AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

In Brief

Krish Patel joins Sarah Cannon as director of lymphoma research

Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.

November 22, 2024

Vol.50 No.44

Clinical Trials & Tribulations

How we improved the treatment of Hodgkin lymphoma

Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy.

November 15, 2024

Vol.50 No.43

By Alex Herrera